These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 17319926

  • 1. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.
    Montano-Loza AJ, Carpenter HA, Czaja AJ.
    Am J Gastroenterol; 2007 May; 102(5):1005-12. PubMed ID: 17319926
    [Abstract] [Full Text] [Related]

  • 2. Remission in autoimmune hepatitis: what is it, and can it ever be achieved?
    Al-Chalabi T, Heneghan MA.
    Am J Gastroenterol; 2007 May; 102(5):1013-5. PubMed ID: 17489784
    [Abstract] [Full Text] [Related]

  • 3. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.
    Czaja AJ, Menon KV, Carpenter HA.
    Hepatology; 2002 Apr; 35(4):890-7. PubMed ID: 11915036
    [Abstract] [Full Text] [Related]

  • 4. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.
    Czaja AJ, Carpenter HA, Lindor KD.
    Hepatology; 1999 Dec; 30(6):1381-6. PubMed ID: 10573515
    [Abstract] [Full Text] [Related]

  • 5. Consequences of treatment withdrawal in type 1 autoimmune hepatitis.
    Montano-Loza AJ, Carpenter HA, Czaja AJ.
    Liver Int; 2007 May; 27(4):507-15. PubMed ID: 17403191
    [Abstract] [Full Text] [Related]

  • 6. Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome.
    Maruyama S, Hirayama C, Horie Y, Yorozu K, Maeda K, Inoue M, Fujii Y, Umeki K, Koda M.
    Hepatogastroenterology; 2007 Mar; 54(74):493-8. PubMed ID: 17523306
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.
    Montano-Loza AJ, Carpenter HA, Czaja AJ.
    Hepatology; 2007 Oct; 46(4):1138-45. PubMed ID: 17668882
    [Abstract] [Full Text] [Related]

  • 9. Clinical subgroup of autoimmune hepatitis type 1 sustaining remission without additional drugs.
    Ohana M, Hajiro K, Okazaki K, Haga H, Kobashi Y.
    Hepatogastroenterology; 1998 Oct; 45(23):1667-72. PubMed ID: 9840126
    [Abstract] [Full Text] [Related]

  • 10. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.
    Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, Azoulay D, Castaing D, Samuel D.
    Liver Transpl; 2007 Jul; 13(7):996-1003. PubMed ID: 17370335
    [Abstract] [Full Text] [Related]

  • 11. Risk factors for recurrence of autoimmune hepatitis after liver transplantation.
    Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P.
    Liver Transpl; 2009 Oct; 15(10):1254-61. PubMed ID: 19790153
    [Abstract] [Full Text] [Related]

  • 12. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome.
    Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA.
    Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1389-95; quiz 1287. PubMed ID: 18840547
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.
    Czaja AJ, Carpenter HA.
    J Hepatol; 2004 Apr; 40(4):646-52. PubMed ID: 15030981
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis.
    Wang Q, Selmi C, Zhou X, Qiu D, Li Z, Miao Q, Chen X, Wang J, Krawitt EL, Gershwin ME, Han Y, Ma X.
    J Autoimmun; 2013 Mar; 41():140-5. PubMed ID: 23187010
    [Abstract] [Full Text] [Related]

  • 17. Histological findings in chronic hepatitis C with autoimmune features.
    Czaja AJ, Carpenter HA.
    Hepatology; 1997 Aug; 26(2):459-66. PubMed ID: 9252159
    [Abstract] [Full Text] [Related]

  • 18. Frequency and nature of the variant syndromes of autoimmune liver disease.
    Czaja AJ.
    Hepatology; 1998 Aug; 28(2):360-5. PubMed ID: 9695997
    [Abstract] [Full Text] [Related]

  • 19. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis.
    Czaja AJ, Carpenter HA.
    Liver Int; 2003 Apr; 23(2):116-23. PubMed ID: 12654134
    [Abstract] [Full Text] [Related]

  • 20. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis.
    Miyake Y, Iwasaki Y, Terada R, Takagi S, Okamaoto R, Ikeda H, Sakai N, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y.
    J Hepatol; 2005 Dec; 43(6):951-7. PubMed ID: 16143423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.